Posted by Michael Wonder on 14 Dec 2020
Gannex received U.S. FDA fast track designation for its NASH drug candidate ASC42, an FXR agonist
13 December 2020 - Gannex announced today that it received fast track designation from the U.S. FDA for its non-alcoholic steatohepatitis drug candidate ASC42.
Gannex received the investigational new drug application approval for ASC42 from the U.S. FDA in October this year.
ASC42 is an in-house developed, novel non-steroidal, selective, potent farnesoid X receptor agonist with best-in-class potential.
